Type V Collagen Induced Tolerance Suppresses Collagen Deposition, TGF-β and Associated Transcripts in Pulmonary Fibrosis

Ragini Vittal, Elizabeth A. Mickler, Amanda J. Fisher, Chen Zhang, Katia Rothhaar, Hongmei Gu, Krista M. Brown, Amir Emtniazdjo, Jeremy M. Lott, Sarah B. Frye, Gerald N. Smith, George E. Sandusky, Oscar W. Cummings, David S. Wilkes

1 Center for Immunobiology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 2 ImmuneWorks Inc., Indianapolis, Indiana, United States of America, 3 Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America

Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by progressive scarring and matrix deposition. Recent reports highlight an autoimmune component in IPF pathogenesis. We have reported anti-col(V) immunity in IPF patients. The objective of our study was to determine the specificity of col(V) expression profile and anti-col(V) immunity relative to col(I) in clinical IPF and the efficacy of nebulized col(V) in pre-clinical IPF models.

Methods: Col(V) and col(I) expression profile was analyzed in normal human and IPF tissues. C57-B6L mice were intratracheally instilled with bleomycin (0.025 U) followed by col(V) nebulization at pre-/post-fibrotic stage and analyzed for systemic and local responses.

Results: Compared to normal lungs, IPF lungs had higher protein and transcript expression of the alpha 1 chain of col(V) and col(I). Systemic anti-col(V) antibody concentrations, but not of anti-col(I), were higher in IPF patients. Nebulized col(V), but not col(I), prevented bleomycin-induced fibrosis, collagen deposition, and myofibroblast differentiation. Col(V) treatment suppressed systemic levels of anti-col(V) antibodies, IL-6 and TNF-α; and local IL-17a transcripts. Compared to controls, nebulized col(V)-induced tolerance abrogated antigen-specific proliferation in mediastinal lymphocytes and production of IL-17A, IL-6, TNF-α and IFN-γ. In a clinically relevant established fibrosis model, nebulized col(V) decreased collagen deposition. mRNA array revealed downregulation of genes specific to fibrosis (Tgf-b1, Il-1b, Pdgfb), matrix (Acta2, Col1a2, Col3a1, Lox, Itgb1/6, Itga2/3) and members of the TGF-β superfamily (Tgfbr1/2, Smad2/3, Ltbp1, Serpine1, Nfkβ5p1/Cebp).

Conclusions: Anti-col(V) immunity is pathogenic in IPF, and col(V)-induced tolerance abrogates bleomycin-induced fibrogenesis and down regulates TGF-β-related signaling pathways.

Introduction

Idiopathic Pulmonary Fibrosis (IPF) is a fatal disease with no effective treatment and a three year mean survival rate [1]. The early IPF lesion is believed to be alveolitis that leads to thickening of the alveolar wall and epithelial cell death, eventually culminates in fibrogenic fact which is characterized by overexpression of collagen types I [col(I)] and V [col(V)] [2]. However, the relative quantities of total col(I) to col(V) and their respective individual chains in the IPF lung are unknown.

Type V collagen ([col(V)]) is a minor collagen normally sequestered within the lung interstitium and therefore, hidden from the immune system. Remodeling, a characteristic feature of IPF, leads to col(V) exposure and overexpression which in turn is associated with the development of anti-col(V) immunity - indicating an autoimmune aspect in IPF pathogenesis. Specifically, up to 60% of IPF patients have anti-col(V) reactive T cells [3], and nearly half develop specific systemic antibody responses [4]. Persistent immune responses and resulting dysregulated tissue healing accelerates the pathogenic conditions towards fibrosis and accumulation of extracellular matrix components [5]. When autoimmune or other agents cause epithelial injury, matrix metalloproteinases [6] are expressed to gain access to damaged tissues. Subsequently, pro-inflammatory chemokines and growth factors activate the immune system, leading to fibrogenesis.

Citation: Vittal R, Mickler EA, Fisher AJ, Zhang C, Rothhaar K, et al. (2013) Type V Collagen Induced Tolerance Suppresses Collagen Deposition, TGF-β and Associated Transcripts in Pulmonary Fibrosis. PLoS ONE 8(10): e76451. doi:10.1371/journal.pone.0076451

Copyright: © 2013 Vittal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by NIH-NHLBI-Lung Tissue Research Consortium and NIH-NHLBI-HL109288 to RV; NIH-NHLBI-HL067177 to DSW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: David S. Wilkes is a co-founder of ImmuneWorks, Inc., a biotechnology company involved in developing therapeutics for various forms of lung diseases. Katia Rothhaar is the Director of Research Operations while Sarah Frye is a Research Technician working at ImmuneWorks, Inc. All other authors declare no competing interests. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: dwilkes@iupui.edu
Anti-Fibrotic Effects of Col(V) in IPF

factors are recruited to the site of injury. During this phase, the chemokine cocktail leads to myofibroblast accumulation and deposition of extracellular matrix components such as integrins [7–9], fibronectins [10] and collagens [11]. TGF-β, a master regulator of the fibrogenic process [12], is intricately involved in the crosstalk of other pro-fibrotic molecules, particularly PDGF [13] and IL-1β [14]. In this pro-fibrotic environment, intricate interactions which exist between specific key players, for example - TGF-β and integrins, accelerate fibrogenesis. Integrins, which are receptors for cell-cell and cell-matrix adhesion, has been reported to activate latent TGF-β [9], specifically αVβ6 integrins. Similarly, TGF-β has been reported to upregulate integrin expression [15]. Notably, collagens may bind to αβ1 integrins via the RGD binding site, since it is recognized in all ligands [16]. Collagen type I has been reported to bind to α3β1 integrins via the DGEA binding site [17]. Interestingly, the effects of col(V)-induced tolerance on the gene expression of integrins and other fibrosis related genes, in IPF are unknown.

Col(V)-induced tolerance reportedly downregulates TGF-β in an experimental model of systemic sclerosis [18]. Col(V)-induced tolerance by systemic administration abrogates obliteratorive bronchiolitis (OB) post lung transplant [19] and bleomycin-induced acute injury [20]. Since col(V) is overexpressed in IPF and associated with anti-col(V) immuminity, then in the current study we tested the hypothesis that nebulizing col(V) to significantly scarred lungs will arrest progression of fibrosis and that col(V)-induced tolerance by inhalation will attenuate pro-fibrotic signaling in a pre-clinical model of IPF. Our findings suggest that col(V)-induced tolerance effectively mitigates lung fibrosis and down regulates TGF-β and related signaling pathways.

Materials and Methods

Human Studies

All protocols were approved by the Institutional Review Board, IUSM.

Plasma and frozen tissues from IPF patients were obtained from the Lung Tissue Research Consortium (LTRC) sponsored by NIH/NHLBI. The LTRC collected medical data and tissues from large cohorts of patients to study the cause, early detection and best treatment for IPF and other similar lung diseases. A written consent was obtained from patients by LTRC and this questionnaire is available at their public domain http://www.ltrcpublic.com/docs/LTRC_Consent_Jul_2010.pdf. Plasma from IPF patients were also provided by ImmuneWorks, Inc. The samples were collected by written consent from patients enrolled in a clinical trial. The patient selection criteria are available in the public domain: http://www.clinicaltrials.gov/ct2/show/NCT01199887?term=pulmonary+fibrosis+immune+works&rank=1. Therefore, the individuals in this manuscript have given written informed consent (as outlined in PLOS consent form) to publish these research details. Pathologist-certified paraffin-embedded lung tissues and normal lung specimens were also procured from the Department of Pathology, Indiana University School of Medicine (IUSM).

Real Time PCR

Total RNA was isolated from two 20 μm scrolls of formalin-fixed paraffin embedded tissue using RecoverAllTM Total Nucleic Acid Isolation Kit (Ambion) according to manufacturer’s instructions. cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Alpha 1 and 2 chains for col(I) and col(V) and GAPDH were performed using the Assays-on-DemandTM gene expression kits (Applied Biosystems, Foster City, CA) on a SmartCycler (Cepheid, Sunnyvale, CA). qRT-PCR for β-actin, IL-17A-FW:CAATAGTGTAGCCCTGGCGGT, RV:AGAGGGAAAATCGTGGGTGAC, IL-17A-FW:CTGTGTCCTCCTGATGCTGTGG, RV:ATGTGGTGTTCCAGCTTTC.

Mouse Fibrosis PCR Microarrays

Murine lung mRNA was used to generate cDNA. The Mouse Fibrosis PCR array- RT² Profiler PCR Arrays version 3.0 (SA Biosciences, Qiagen, Valencia, CA) was used as per manufacturer’s instructions and array data were analyzed using Qiagen PCR Array Data Analysis software. The array data is provided in Table S1.

Circulating col(V) and col(I) antibody detection

Known volumes of plasma (10 μl) were incubated with microsphere beads coated with col(V) or col(I) and the signal was detected by flow cytometry as previously described [21]. Results of the duplicate reactions were expressed as Mean Fluorescent Intensity (MFI) as a fold change compared to pooled normal plasma.

Pepsin digestion

Frozen IPF and normal lung tissues were homogenized and subjected to pepsin extraction by lysing the tissues in a buffer containing pepsin in 0.2M acetic acid. The lysates were then subjected to dialysis, lyophilization, followed by careful weighing and re-suspension in lysis buffer at a concentration of 1 mg/ml. Pepsin-digested samples were equally loaded at 15 μg in a fixed 5% concentration agarose gel and electrophoresed as previously described [22]. Densitometry measurements: Bands corresponding to the individual chains of col(V) or col(I) was measured in normal and IPF lungs using NIH Image J. The col(V) protein standard was used as a control on the exposure time. Values were then expressed as Mean ± SEM.

Animal Studies

The Indiana University School of Medicine Animal Care and Use Committee (LACUC) approved the animal protocols used in this study. Female C57BL/6 mice (6–8 weeks of age) were purchased from Jackson Laboratory (Bar Harbor, ME). After a 5 day period of acclimatization, mice were administered intratracheal PBS or bleomycin (0.025 U) as previously described [23]. Based on previous studies, we used varying doses of col(V): 4.16, 5.5, and 8.33 mg/kg bodyweight, at a final volume of 100 μl, and nebulized it to a mouse of average body weight of 18 gm. Mice were nebulized in a conscious state using Aeroneth® Lab Nebulizer, which is designed to produce highly respirable aerosol particles with sizes averaging between 2.5 μm-4.0 μm. Historically, aerosolized drug particles with a size of ~3.0 μm has been documented as optimal for penetration, retention and maximal therapeutic effectiveness in the lung [24]. Lungs were processed for immunohistochemical (IHC) staining or stored at ~20°C until further analyses.
Statistical analysis

Statistical analysis was performed using Student’s t test, one-way ANOVA with Bonferroni post hoc test using GraphPad Prism version 3.0 for Windows GraphPad Software (San Diego, CA, www.graphpad.com). Statistical significance was defined at \( p<0.05 \).

Additional descriptive material for methods used in this study is provided in File S1. The raw array data for the array analyses is provided in Table S1.

Results

Col(V) protein and mRNA overexpression in the fibrotic foci of lungs with IPF

Col(V) exists in the lung as the predominant heterotrimer, \([\alpha_1(V)]_2 \cdot [\alpha_2(V)]\). The activity of this molecular form to bind to heparin at physiological salt concentrations may be attributed to a proteolytic \(\text{NH}_2\)-terminal 30-kDa fragment of the \(\alpha_1(V)\) chain [25]. Parra and colleagues have demonstrated the distribution of

![Figure 1](image-url)
col(V) in IPF [26]. However, the relative quantitative distribution of col(I) to col(V) and the expression pattern of the individual chains of col(V) and col(I) in the IPF lungs are largely uncertain. In contrast to normal lungs wherein we observed strong expression of total col(I), but not col(V), in the interstitium; both col(I) and col(V) were expressed heavily in IPF lungs (Figure 1A). We observed a similar trend when we analyzed pepsin-digested normal and IPF lungs for protein expression levels of alpha 1 [α1(V)] and alpha 2 [α2(V)] chains of col(V) (Figure 1B). The expression levels of α1(V) and α2(V) were ~2.5–3 fold higher than the normal tissues. Notably, α1(V) levels were higher than α2(V) in the IPF lungs (p<0.01). Similarly, α1(I) levels were higher in IPF patients compared to normal donors. IPF lungs had higher α1(I) levels than α2(V) (p<0.0001) (Figure 1B,C; Figure S1). At the transcript level, we observed higher expression of α1(V) (Col5a1) and α1(I) (Col1a1) in the IPF lungs compared to normal and that Col1a1 was ~6 fold higher than Col5a1 in IPF (Figure 1D). Collectively, these studies demonstrate that col(I), particularly α1(I), is overexpressed at the transcript and protein level in IPF.

**Circulating col(V)-specific antibody responses in IPF**

Although we have reported anti-col(V) cellular immunity in IPF [3], the relative circulating antibody levels of col(V) and col(I) are unknown. We investigated a cohort of 40 patients diagnosed with IPF as per ATS criteria as previously described [3]. The cohort has a gender distribution of 15 females and 25 males and their average age is 64.3 years with a standard deviation of 7.78. We observed that compared to normal healthy volunteers, anti-col(V) antibodies were detected at very low levels in all patients studied. The above studies demonstrate that IPF is associated with systemic anti-col(V) antibodies specifically.

**Bleomycin-induced fibrosis results in col(V) overexpression and production of anti-col(V) antibodies**

We next determined if the bleomycin-induced lung injury, as a model for IPF, results in col(V) overexpression, and anti-col(V) cellular and humoral immunity. Indeed, bleomycin-induced fibrosis was associated with overexpression of col(V) (Figure 3A), and development of anti-col(V) antibodies (Figure 3C) in a manner similar to that observed in clinical IPF. Since we have observed data showing that col(V) is the target of an autoimmune response in IPF in both pre-clinical and clinical studies, we next determined if col(V) could be utilized as a tolerogen to prevent fibrosis. Braun and colleagues have demonstrated that systemic administration of col(V) inhibits bleomycin-induced acute lung injury using measures of lung inflammation [20]. Since introducing antigens to the lung mucosa may result in tolerance, we nebulized col(V) into the lungs of mice using the experimental model of chronic bleomycin injury as illustrated in Figure 3B, followed by a systematic assessment of parameters associated with fibrosis. Compared to bleomycin-injured mice, nebulizing col(V) resulted in a reduction in anti-col(V) antibodies (Figure 3C), hydroxyproline concentration (Figure 3D), reduced connective tissue deposition as shown by trichrome staining and blunted myofibroblasts differentiation as observed by expression for α-smooth muscle actin (α-SMA) (Figure 3E).

Type I collagen [col(I)], is the major lung collagen, and is highly expressed in IPF lungs [27]. However, high levels of circulating anti-col(I) antibodies were not detected in IPF patients (Figure 2) or in bleomycin-induced fibrosis (Figure 4B). Furthermore, nebulizing col(I) did not prevent fibrosis induced by bleomycin (Figure 4C). Our studies suggest that the fibro-protective effects of nebulizing a native lung protein, col(V) in particular, are a specific response.

**Tolerance induction of col(V) suppresses local T lymphocyte proliferation and pro-inflammatory/pro-fibrotic cytokine expression**

We have previously demonstrated lung allograft rejection is in part mediated by anti-col(V) immunity and that col(V)-induced tolerance abrogated the rejection response [28] and Wilson and colleagues had reported that bleomycin-induced lung fibrosis may be T cell dependent [29]. We next determined if immune tolerance was the mechanism of col(V)-induced prevention of lung fibrosis we had earlier shown in Figure 3. Data in Figure 5 shows that mediastinal lymph node lymphocytes isolated from col(V)-treated mice do not proliferate in response to col(V) when presented by autologous antigen presenting cells, therefore indicating col(V)-induced tolerance (Figure 5A). IL-17, IL-6, and TNF-α have all been linked to fibrosis [29–31]. Therefore, we next examined the cytokines produced in the supernatants of the mixed leukocyte reactions reported in Figure 5A. Notably, col(V)-induced tolerance was associated with IL-17A, IL-6 and TNF-α (Figure 5B). We also noted a reduction in IFN-γ but not IL-10 (Figure 5B). These changes were also observed systemically by data showing lower serum levels of IL-6 and TNF-α (Figure 5C, D), as well as lower lung transcript levels for IL-17a in col(V)-treated mice (Figure 5E), albeit at an earlier time point at day 14 wherein we could detect higher mRNA expression of IL-17a in bleomycin-injured mice. Collectively, the above data indicates that immune tolerance induced by col(V) protects against bleomycin injury by...
blunting T cell activation and the associated systemic and local expression of pro-inflammatory and pro-fibrotic cytokines.

Col(V) prevents collagen accumulation in established fibrosis

We next determined if nebulized col(V) would arrest ongoing collagen deposition in a model of chronic fibrosis induced by bleomycin. Based on efficacy established in preliminary studies, we nebulized 8.33 mg/kg bodyweight of col(V) protein three times a week beginning at day 14 post bleomycin injury, a time when fibrosis is established [32], followed by sacrifice at day 28 as schematically presented in Figure 6A. Notably, we observed significant protection from fibrosis (Figure 6B; top panel) and attenuated collagen deposition as observed by Masson’s trichrome staining. Extensive collagen deposition was observed with bleomycin injury while col(V) nebulized lungs, similar to normal lungs, had collagen deposition around airways and vasculature. Original magnifications: 10×. (Figure S2A: 1×). Lung tissue sections were immunostained against α-smooth muscle actin (α-SMA) or IgG. Streptavidin-conjugated horseradish peroxidase was used with 3,3′-diaminobenzidene as substrate (brown) and nuclei were counterstained with hematoxylin (blue). Original magnifications: 20×.

Figure 3. Tolerance induction of Col(V) protects against bleomycin-induced fibrosis. (A) Col(V) overexpression was detected in 21 day post bleomycin injury by labeling with rhodamine and counterstained with DAPI. (Original magnification, 10×). (B) Schematic illustration of the experimental design. (C) Circulating antibodies specific to col(V) were detected in 21 day post bleomycin injury mice. Values represent mean ± SEM; number of animals: PBS = 5, BLEO = 6 and BLEO+col(V) Neb = 4. Compared to bleomycin group, * p<0.001; ** p<0.01; one-way ANOVA, post hoc test: Bonferroni. (D) Collagen deposition was measured quantitatively by assaying for hydroxyproline concentrations from the whole left lung day 21 post bleomycin injury+col(V) treatment. Values represent mean ± SEM; n = 7 mice/group. Compared to bleomycin group, ** p<0.01; * p<0.05 one-way ANOVA, post hoc test: Newman-Keuhl’s. (E) At day 21 post bleomycin injury, lung tissue sections were stained for H&E and Masson’s blue trichrome staining.
staining for collagen (Figure 6B; lower panel) and hydroxyproline content (Figure 6C). Notably, at the time of nebulization of col(V), there was significantly higher hydroxyproline concentrations in the lung at day 14 post bleomycin instillation compared to PBS-instilled lungs (p < 0.001). We then observed that compared to day 14 post bleomycin, at day 28 post bleomycin, the lungs had higher hydroxyproline concentration (p < 0.01). Compared to day 28 post bleomycin, col(V) nebulization significantly attenuated hydroxyproline concentrations in the lung (p < 0.001). Through our studies, we conclude that delayed administration of col(V) in a nebulized form is effective in arresting the progression of established fibrosis.

**Nebulized col(V) downregulates local fibrosis-related transcripts**

To further investigate mechanisms underlying the beneficial effects of col(V) in established fibrosis, we next analyzed transcript expression for fibrosis-related genes in the bleomycin model. In a
comparison of PBS or bleomycin-instilled lung, we observed upregulation of genes from five major functional classes implicated as fibrogenic factors in IPF (Table 1). Nebulized delivery of col(V), suppressed bleomycin-induced genes listed in the following functional categories: integrins (Itga1, Itga2, Itgb1, Itgb6, Figure 7), pro-fibrotic growth factors (Tgfb, Il1b, Pdgfb, Figure 7), fibrosis and matrix-related molecules (Acta2, Col1a2, Col3a1, Mmp2, Lox, Figure 8) and members of the TGF-beta superfamily (Tgfbr1/2, Smad2/3, Ltbp1, Serpine1, Nfkb/Sp1/Cebpb, Figure 9) in addition to Snai-1 and Stat6 (Figure 9). These data suggest that treatment with col(V) may lead to attenuation of multiple pro-fibrotic genes involved in the pathogenesis of IPF.

**Discussion**

Col(V), a minor collagen in the lung, is sequestered within the fibrils of type I collagen, the major pulmonary collagen. Our studies demonstrate the systemic production of anti-col(V)
autoantibodies as a specific response and associated local expression of individual alpha chains of col(V) in clinical IPF specimens. Accordingly, tolerizing mice with nebulized col(V), but not col(I), prevented lung fibrosis and lower production of inflammatory cytokines. The current study also shows that nebulized col(V) protein arrests further development of bleomycin-induced fibrosis by the suppression of multiple fibrosis-related genes, specifically members of the TGF-β superfamily. To the best of our knowledge, the current study is the first to show the efficacy of nebulized therapy of a native protein in the treatment of established fibrosis. mRNA transcript data indicate that the beneficial effect of col(V) likely involves multiple pathways involved in fibrogenesis.

Figure 6. Col(V) treatment protects against established fibrosis. (A) Schematic illustration of the experimental design. (B) At day 28 post bleomycin injury, lung tissue sections were stained for H&E and Masson’s blue trichrome staining. Extensive collagen deposition was observed with bleomycin injury while col(V) nebulized lungs, similar to normal lungs, had collagen deposition around airways and vasculature. Original magnifications: 10×. (Figure S2C: 1×). (C) Collagen deposition was measured quantitatively by assaying for hydroxyproline concentrations from the whole left lung day 28 and day 14 post bleomycin injury+col(V) treatment. Values represent mean ± SEM; n = 12 mice/group; * p < 0.001 for day 28 bleomycin vs. day 28 PBS and day 28 col(V) (Neb); day 14 bleomycin vs. day 14 PBS; day 28 bleomycin vs. day 14 bleomycin; one-way ANOVA, post hoc test: Bonferroni.
doi:10.1371/journal.pone.0076451.g006
Previous reports by Parra and colleagues describe the role of col(V) in the pathogenesis of IPF by illustrating the distributions of col(V) in two different lung compartments and by using three-dimensional reconstruction to evaluate the amount of collagen [26]. The potential caveat therein may possibly be the green auto fluorescence emitted by lungs resulting in interference of measurements. Our studies demonstrate the overexpression of the individual chains of col(V) proteins in IPF lungs, which was

Table 1. List of bleomycin-induced genes modulated by col(V) treatment.

| Functional Class | Unigene | Symbol | Gene Description | Upregulation | Downregulation |
|------------------|---------|--------|------------------|--------------|----------------|
| Integrins        |         |        |                  |              |                |
| Mm.5007 Itga2    |         |        | Integrin alpha 2 | 0.001        | 0.001          |
| Mm.57035 Itga3   |         |        | Integrin alpha 3 | 0.05         | 0.001          |
| Mm.263396 Itb1   |         |        | Integrin beta 1  | 0.001        | 0.001          |
|                  |         |        | (fibronectin receptor beta) |            |                |
| Mm.98193 Itb6    |         |        | Integrin beta 6  | 0.01         | 0.01           |
| Cytokines/Growth Factors | |        |                  |              |                |
| Mm.248380 Tgfb1 |         |        | Transforming growth factor, beta 1 | 0.05 | 0.01 |
| Mm.222830 Il1b  |         |        | Interleukin 1 beta | 0.001 | 0.001 |
| Mm.144089 Pdgfb |         |        | Platelet derived growth factor, B polypeptide | 0.05 | 0.05 |
| Fibrosis, matrix and matrix-binding molecules | |        |                  |              |                |
| Mm.213025 Acta2 |         |        | Actin, alpha 2, smooth muscle, aorta | 0.05 | 0.01 |
| Mm.277792 Col1a2 |         |        | Collagen, type I, alpha 2 | 0.05 | 0.05 |
| Mm.249555 Col3a1 |         |        | Collagen, type III, alpha 1 | 0.05 | 0.05 |
| Mm.172 Lox      |         |        | Lysyl oxidase     | 0.01         | 0.01           |
| Mm.29564 Mmp2   |         |        | Matrix metalloproteinase 2 | 0.05* | 0.05* |
|                  |         |        |                  |              |                |
| Mm.439656 Cebpb |         |        | CCAAT/enhancer binding protein (C/EBP), beta, latency associated peptide (LAP) | 0.05* | 0.05* |
| Members of the TGF-beta superfamily | |        |                  |              |                |
| Mm.197552 Tgfb1 |         |        | Transforming growth factor, beta receptor I, ALK5 | 0.05 | 0.01 |
| Mm.172346 Tgfb2 |         |        | Transforming growth factor, beta receptor II | 0.001 | 0.001 |
| Mm.269747 Ltbp1 |         |        | Latent transforming growth factor beta binding protein 1 | 0.01 | 0.01 |
| Mm.391091 Smad2 |         |        | MAD homolog 2 (Drosophila) | 0.01 | 0.05 |
| Mm.7320 Smad3   |         |        | MAD homolog 3 (Drosophila) | 0.05 | 0.05 |
| Mm.250422 Serpine1 |       |        | Serine (or cysteine) peptidase inhibitor, clade E, member 1, PAI-1 | 0.05 | 0.05 |
| Transcription factors | |        |                  |              |                |
| Mm.2093 Snai1   |         |        | Snail homolog 1 (Drosophila) | 0.05* | 0.01* |
| Mm.256765 Nfkb  |         |        | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105 | 0.05 | 0.05 |
| Mm.4618 Sp1     |         |        | Trans-acting transcription factor 1 | 0.05 | 0.05 |
| Mm.121721 Stat6 |         |        | Signal transducer and activator of transcription 6 | 0.01 | 0.01 |

*indicates Newman-Keul’s-adjusted P value.
doi:10.1371/journal.pone.0076451.t001
determined by pepsin digestion of the lungs followed by careful systematic extraction of total collagen [22]. The mRNA expression of col(V) was analyzed in IPF tissue sections with confirmed fibrotic lesions. Similarly, our pre-clinical studies provide evidence that nebulized col(V), but not col(I), blunts circulating autoantibodies and renders col(V)-specific immunosuppression with attenuation of associated cytokines. Braun and colleagues examined effects of systemically tolerized col(V) in a bleomycin model of acute lung injury by using measures of inflammation [20]. We present effects of nebulized col(V) in a bleomycin model of chronic fibrosis using hallmarks of bleomycin-induced fibrosis/IPF: a) T cell activation, b) collagen deposition and c) myofibroblast differentiation.

In order to simulate the relevant clinical setting wherein lungs of IPF patients at the time of diagnosis are significantly scarred, we used the bleomycin model of established fibrosis. Henderson and colleagues have previously demonstrated the effectiveness of using a therapeutic model examining bleomycin-induced lung fibrosis in

Figure 7. Col(V) treatment downregulates integrins, TGF-β and other pro-fibrotic cytokines. At day 28 post bleomycin injury, lung tissues were homogenized and cDNA was analyzed for fibrosis-specific gene expression analyses.
doi:10.1371/journal.pone.0076451.g007
which an intervention was administered at the time of established fibrosis to determine if fibrosis could be reversed [32]. Our demonstration that nebulized col(V) arrests the progression of established fibrosis possibly via mitigation of multiple key fibrotic pathways (Figure 10). However, these pathways appear to be centrally revolving around TGF-β and its associated downstream signaling molecules. Even more significantly, a few integrins, the major receptors for cell adhesion to extracellular matrix proteins and other cells, are downregulated in response to col(V) treatment and are discussed here. αVβ6 integrin (Itgb6) activates latent TGF-β and hence lack of this gene [33] or its inhibition [34] protects against lung fibrosis. α3β1 integrin (Itgb1) has been implicated in activation of latent TGF-β and hence epithelial-mesenchymal transition [35] and additionally, it facilitates β-catenin-Smad3 crosstalk to promote myofibroblast formation and survival [9]. α2β1 integrin (Itga2), a receptor for type I collagen, is reportedly upregulated in response to TNF-α in IPF lung-derived fibroblasts [36].

While bleomycin-induced TGF-β and members of the TGF-β superfamily are suppressed by col(V) nebulization, other profibrotic molecules which crosstalk with TGF-β are suppressed by col(V) and they are discussed below: (i) IL-1β causes acute lung injury via integrin-dependent mechanisms, including αVβ6 integrin [7] and (ii) PDGF signaling pathways [37]. Increased levels of lysyl oxidase (LOX), an amine oxidase critical for the initiation of collagen and elastin cross-linking [38], increased mRNA levels of collagen type I (Col1a2), collagen type III (Col3a1) and matrix metalloproteinase (Mmp2) have been reported in murine models of lung fibrosis [39]. Interestingly, Serpinc1 - also known as the TGF-β-regulated protein PAI-1 – has been reported to directly correlate with collagen accumulation and that the TGF-β/PAI-1 signaling axis plays a vital role in myofibroblast survival [40]. The nuclear transcription factors which are blocked by col(V) treatment and implicated in pulmonary fibrosis are NF-κB [41], Sp1 [42] and CCAAT/enhancer-binding protein β (Cebpb) [43], SMAI [44] and STAT6 [45]. While Velosa et al [18] have demonstrated that col(V)-induced tolerance downregulates TGF-β in an experimental model of systemic sclerosis, they had not investigated other related pathways which might likely fuel the pro-fibrotic signaling. Our studies suggest that col(V) likely confers its fibroprotective effects by targeting integrins, in addition to TGF-β and its associated-signaling pathways. Notably, we detected some bleomycin-induced genes which were unchanged by col(V) treatment and other genes which were unchanged due to bleomycin induction at the determined time of analyses (Figure S3).

In this report, we present evidence which identifies col(V) in an emerging class of target molecules combating specific autoimmune/fibrotic responses. Recent investigations have focused on certain pathologic inflammatory responses which may be due to autoimmunity wherein self-reactive circulating autoantibodies have been detected among patients and associated with acute disease process [46,47]. While early studies show presence of circulating immune complexes [48]; a recent report has identified mutations in autoimmune regulator gene as a link between autoimmune responses and defective central immunotolerance in IPF [49]. Hence, circulating antibodies to self-antigens have been widely documented but their roles as potential immunotherapy has not been demonstrated. A prior study from our laboratory has identified the localization of col(V) in the apical surface of airway
epithelial cells [21]. Interestingly, most of the documented evidence on auto-antibodies has been related to proteins specific to the epithelium which is the primary line of defense against injury due to pro-inflammatory/pro-fibrotic cytokines, pathogenic microbes and other agents such as the reactive oxygen species.

The limitations in this study would call for longitudinal studies in clinical tissues to understand the trend of antibody response relative to disease progression. Similarly, in our mouse models, elucidation of the functional and phenotypic effects of col(V) antibodies and their products on key cell types involved in the pathogenesis of IPF, such as epithelial, endothelial or mesenchymal cells. The interaction site between col(V) and integrins coupled with their functional and phenotypic effects in epithelial and mesenchymal cells are unknown. Therefore, the role of potential signaling molecules unraveled in this study, in addition to the effect of col(V) antibodies on impaired epithelialization, tissue repair and matrix remodeling, which are typical features of IPF,

Figure 9. Col(V) treatment downregulates TGF-β associated receptors, signaling molecules and transcription factors. At day 28 post bleomycin injury, lung tissues were homogenized and cDNA was analyzed for fibrosis-specific gene expression analyses. doi:10.1371/journal.pone.0076451.g009
will be the target of our future studies in understanding this antigen.

In summary, we present evidence that autoimmunity to col(V) has a role in the pathogenesis of IPF. These studies also provide further insight for potential mechanisms, particularly TGF-β-related signaling molecules, which may be driving the auto-antigen specific immunosuppression for IPF.

**Supporting Information**

**Figure S1** Pepsin digested lung homogenates (15 μg) and corresponding standards run in a 5% gel and Coomassie stained. Image shown here is representative of 3 normal and 5 IPF tissues. (TIF)

**Figure S2** A. Tolerance induction of col(V) protects against bleomycin-induced fibrosis. H&E and trichrome images of data presented in Figure 3. B. Tolerance induction of col(I) does not protect against bleomycin-induced fibrosis. H&E and trichrome images of data presented in Figure 4. C. Col(V) treatment protects against bleomycin-induced fibrosis. H&E and trichrome images of data presented in Figure 4. Original magnifications: 1×. (TIF)

**Figure S3** Hierarchical clustergram of all 80 genes modulated by col(V) treatment. (TIF)

**Table S1** Excel file with raw data from the PCR-based gene array is provided in Table S1 (Supplemental Information-5). (XLS)

**File S1** Supplementary Methods. (DOCX)

**Acknowledgments**

Bovine amnion collagen type V protein was a generous donation by ImmuneWorks, Inc. Bovine amnion collagen type I protein was a generous donation by Dr. David Brand, Vanderbilt University.
Author Contributions
Conceived and designed the experiments: RV DSW. Analyzed the data: RV KR DSW. Wrote the paper: RV DSW. Pepsin digestion of clinical tissues, hydroxyproline analyses: EAM. Blomycin instillations: AF. Real-time PCR on patient and animal tissues: CZ HG. Col(V) antibody analyses on patient and murine plasma: KR KMB SF. Patient demographic analyses: AE. Cytokine bead assay: JML. Received IPF tissues from LT/RC: RV. Provided consultation on col(V) pepsin digestion: GNS. Board-certified pathologists: OWC GES. Patient demographic analyses: AE. Cytokine bead assay: JML.

References
1. Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Kogah BA (1984) Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med 310: 154–166.
2. Streiter RM, Gomperts BN, Keane MP (2007) The role of CXC chemokines in pulmonary fibrosis. J Clin Invest 117: 549–556.
3. Bobadilla JL, Love RB, Jankowska-Gan E, Xu Q, Haynes LD, et al. (2008) Th-17, mononuclear, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 177: 660–668.
4. Burlington WJ, Love RB, Jankowska-Gan E, Xu Q, Haynes LD, et al. (2007) IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 117: 3498–3506.
5. Wilson MS, Wyan TA (2009) Pulmonary fibrosis: pathogenesis, etiology and regulation. Microsom Immu 2: 103–121.
6. Greenlee KJ, Werb Z, Khosrudmand F (2007) Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 87: 69–96.
7. Ganter MT, Roux J, Miyazawa B, Howard M, Frank JA, et al. (2008) Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms. Circ Res 102: 804–812.
8. Katsumoto TR, Violette SM, Sheppard D (2011) Blocking TGF-beta via inhibition of the alphavbeta3 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease. Int J Rheumatol 2011: 208219.
9. Kim KK, Wei Y, Seekers C, Kugler MD, Wolters PJ, et al. (2009) Epithelial cell alphavbeta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 119: 215–224.
10. Muro AF, Moretti FA, Moore BB, Yan M, Arataz HG, et al. (2000) An essential role for fibrocyte cell matrix type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 177: 631–643.
11. Sueblinvong V, Neujahr DC, Mills ST, Roser-Page S, Ritzenthaler JD, et al. (2006) alpha3beta1 integrin-dependent mechanisms. Circ Res 102: 804–812.
12. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J (1997) Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100: 768–776.
13. Fujimoto H, Gahruza EG, Taguchi O, Nishii Y, Nakahara H, et al. (2006) Thiromycin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis. Am J Pathol 168: 1086–1096.
14. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, et al. (2010) Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207: 535–552.
15. Mungur JS, Sheppard D (2011) Cross-talk among TGF-beta signaling pathways, factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 5: 588–599.
16. Le Ro S, Lecoq C, Uvarabaiyemina F, Yakobh Y, Delos B, et al. (2011) Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med 182: 1270–1281.
17. Yamauchi Y, Takahara T, Chambers RA, Veraldi KL, Larregina AT, et al. (2007) Different expression of TNF-alpha receptors and prostaglandin E(2) Production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. Am J Respir Cell Mol Biol 26: 628–634.
18. Ulsamer A, Wei Y, Kim KK, Tan K, Wheeler S, et al. (2012) Axin pathway inhibition of the alphavbeta6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease. Int J Rheumatol 2011: 208219.
19. Chapman HA (1999) A Foxp3 pathway to pulmonary fibrosis. J Clin Invest 104: 1–4.
20. Henderson WR, Jr., Chi EY, Violette SM, Gagnon Y, Tien YT, et al. (2010) Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 107: 14309–14314.
21. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalhorn SL, et al. (1999) The integrin alpha v beta 6 binds and activating latent TGF-beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319–328.
22. Puthawala K, Hadjjanlou N, Jacoby SG, Bayoung E, Zhao Z, et al. (2008) Inhibition of integrin alphav/ betav, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 177: 82–90.
23. Kim KK, Kugler MD, Wolters PJ, Robillard L, Galvez MG, et al. (2006) Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 103: 13109–13115.
24. Vancheri C, Sortino MA, Vossellini F, Dondi C, F, et al. (1990) Different expression of TNF-alpha receptors and prostaglandin E(2) Production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. Am J Respir Cell Mol Biol 4: 136ra171.
25. Chen Y, Sime PJ, Xu H, Williams MA, LaRussa L, et al. (2012) A peptide derived from desmatin ameliorates organ fibrosis. Sci Transl Med 4: 136ra171.
26. Peta PS, Potter JJ, Liu X, Mezei E (2009) Transforming growth factor-beta1 up-regulation of human alpha[alpha] beta[beta] collagen is mediated by S polymers in Smad2 transducting factors. DNA Cell Biol 28: 423–434.
27. Horowitz JC, Rosen D, Simon RH, Simon TH, Thanachali VJ (2008) Plasminogen activation induced pericellular fibronectin proteolysis promotes fibrotic and apoptosis. Am J Respir Crit Care Med 9: 78–87.
28. Lin X, Sime PJ, Xu H, Williams MA, LaRussa L, et al. (2011) Yin阳 y is a novel regulator of pulmonary fibrosis. Am J Respir Crit Care Med 183: 1609–1619.
29. Cristinell L, Grostenhoor-Megnut S, Boursier C, Michel L, Debray MP, et al. (2011) Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 43: 358–368.
30. Nakayama R, Elmore M, Ford CD (1975) Idiopathic interstitial pulmonary fibrosis. An immune complex disease? Am Rev Respir Dis 107: 826–830.
31. Shum AK, De Voss J, Tan CL, Hou Y, Johannes K, et al. (2009) Identification of a new autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance. Sci Transl Med 1: 9ra20.